SavedAdd your journal

Journals / Klinik Psikofarmakoloji Bülteni / 2014 / Cilt: 24 - Sayı: 2

Chin trembling induced by combined use of OROS methylphenidate and procaterol hydrochloride in a boy with ADHD

Rongwang YANG
Jundong FENG
Suhan ZHANG
Zhengyan ZHAO
Rong LI
Pages
168–171
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It raises an awareness of chin trembling as an adverse effect in patients using a combination of methylphenidate and procaterol hydrochloride, especially among those who are younger and underweight.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Recently, asthma has been reported to be a potential comorbidity of attention deficit hyperactivity disorder (ADHD).
📊
Key Findings & Data:The case presented here is that of a 61/2-year-old boy diagnosed as having both ADHD and asthma.
💡
Conclusion & Impact:It raises an awareness of chin trembling as an adverse effect in patients using a combination of methylphenidate and procaterol hydrochloride, especially among those who are younger and underweight.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Recently, asthma has been reported to be a potential comorbidity of attention deficit hyperactivity disorder (ADHD). It is, therefore, possible to have combined use of medications for both ADHD and asthma although, potential adverse reactions are unknown. The case presented here is that of a 61/2-year-old boy diagnosed as having both ADHD and asthma. He presented with chin trembling after the first administration of OROS methylphenidate and procaterol hydrochloride. This is the first report of an adverse event in patients using a combination of these two types of drugs. It raises an awareness of chin trembling as an adverse effect in patients using a combination of methylphenidate and procaterol hydrochloride, especially among those who are younger and underweight.

🔖

Cite This Article

YANG, R., FENG, J., ZHANG, S., ZHAO, Z., LI, R. (2022). Chin trembling induced by combined use of OROS methylphenidate and procaterol hydrochloride in a boy with ADHD. Klinik Psikofarmakoloji Bülteni, Cilt: 24 - Sayı: 2, 168–171. https://ajindex.com/articles/574031

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007
  2. 164(6):942-8. [CrossRef] 2. Biederman J, Kwon A, Aleardi M, Chouinard VA, Marino T, Cole H, et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry 2005
  3. 162(6):1083-9. [CrossRef] 3. Subcommittee on Attention-Deficit/Hyperactivity Disorder
  4. Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011
  5. 128(5):1007-22. [CrossRef] 4. Mogensen N, Larsson H, Lundholm C, Almqvist C. Association between childhood asthma and ADHD symptoms in adolescence--a prospective population-based twin study. Allergy 2011
  6. 66(9):1224-30. [CrossRef] 5. Fasmer OB, Halmoy A, Eagan TM, Oedegaard KJ, Haavik J. Adult attention deficit hyperactivity disorder is associated with asthma. BMC Psychiatry 2011
  7. [CrossRef] 6. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long- term open-label study. J Am Acad Child Adolesc Psychiatry 2003
  8. 42(4):424-33. [CrossRef] 7. http://www.drugcite.com/?q=PROCATEROL%20HCL (available on June 22, 2013) 8. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001
  9. 107(6):E105. [CrossRef] 9. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, et al. A comparison of once-daily extended- release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004
  10. 113(3 Pt 1):e206- 16. [CrossRef] 10. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of- product studies. Arch Gen Psychiatry 2003
  11. 60(2):204-11. [CrossRef] 11. Armstrong RB, Damaraju CV, Ascher S, Schwarzman L, O’Neill J, Starr HL. Time course of treatment effect of OROS(R) methylphenidate in children with ADHD.